Core Insights - Ocugen, Inc. is enhancing its Retina Scientific Advisory Board and Executive Leadership Team to strengthen its expertise and guidance as it aims for three Biologics License Applications (BLAs) in the next three years [1][2] Leadership and Advisory Board Updates - The company has appointed three renowned retinal surgeons to its Retina Scientific Advisory Board to provide innovative therapeutic options for patients with serious retinal diseases [2][3][4][5] - New members include Dr. Jeffrey S. Heier, Dr. Peter K. Kaiser, and Dr. Arshad M. Khanani, who bring extensive experience in retinal research and clinical trials [3][4][5][6] - Dr. Lejla Vajzovic continues as the SAB chair, alongside existing members Dr. David S. Boyer and Dr. Carl D. Regillo [6] Strategic Appointments - Vijay Tammara, PhD, has been appointed as Chief Development Officer, bringing over 32 years of regulatory experience and a track record of successful marketing authorizations [8][9] - Abhi Gupta, MBA, has been named Executive Vice President of Commercial and Business Development, with over 20 years of experience in gene therapy and corporate development [10][11] Company Focus and Goals - Ocugen aims to optimize its R&D and clinical efforts while pursuing strategic partnerships and developing a commercial strategy [7] - The company is focused on delivering paradigm-changing gene therapies for inherited retinal diseases and other blindness conditions affecting millions globally [12]